

# The Innovative Medicines Initiative (IMI)

---



*Update November 2008*

# IMI 1st Call: specific features



- Call Published: 30 April 2008
- Deadline for Stage 1: 15 July 2008
- Call Budget: € 122.7 from EC and € 172 estimated 'in kind contribution' from EFPIA member companies
- 18 topics opened:
  - 6 in "Safety"
  - 7 in "Efficacy"
  - 5 in "Education and Training"
- 138 Expressions of Interests received

# Expressions of Interest submitted to IMI JU (Stage 1)



PILLAR	Number of Expressions of Interest	
	Received	Eligible (Y/N)
Safety	42	41 / 1
Efficacy	77	74 / 3
E & T	19	19 / 0
<b>TOTAL</b>	<b>138</b>	<b>134 / 4</b>
At least one Expression of Interest received in each topic (i.e. all topics have been covered)		
36 tests and 2 fragmented/unallocated text submissions (all non-eligible)		

## Evaluation Stage 1 (I)



- Eligibility check by the IMI JU (deadline, completeness, relevance)
- Evaluation performed by independent external experts, including the coordinators of the EFPIA Consortia
- Each Expression of Interest has been evaluated by 7 to 13 experts (depending on the Panel)
- Remote evaluation by experts from 14 August till 4 September 2008

## Evaluation Stage 1 (II)



- Consensus Panel meetings to discuss and agree on consensus scores for all Expressions of Interest on 9-11 September (all Topics except 7 & 8) and on 16-17 September (Topics 7 & 8)
- One Panel per Topic, except for Topics 7 & 8 (diabetes), 12 & 13 (asthma & COPD) and 14-18 (Education & Training)
- Outcome:
  - One ranked list of Expressions of Interest for each Topic (only those passing the two thresholds)
  - One Evaluation Consensus Form for each Expression of Interest (= feedback to Applicant Consortium)
  - One Summary Evaluation Report per Topic (to be kept at the IMI JU)

## Evaluation of Expressions of Interest by the IMI JU



PILLAR	Number of Expressions of Interest		
	Evaluated	Above threshold	Below threshold
Safety	41	20	21
Efficacy	74	29	45
E & T	19	7	12
<b>TOTAL</b>	<b>134</b>	<b>56 (42%)</b>	<b>78 (58%)</b>

**At least one Expression of Interest above threshold in each topic**

## Next steps: Stage 2



- The three highest ranked Expressions of Interest for each Topic will be:
  - ➔ informed in writing of their position on the ranked list
  - ➔ asked to confirm their willingness to proceed to preparations for Stage 2 – Full Proposal
  - ➔ asked for permission to send copy of their Expression of Interest to the EFPIA consortia
- Preparatory discussions start between EFPIA Consortia and the 1st ranked Expression of Interest, should such preparatory discussions fail – EFPIA consortia proceed to discuss with 2nd ranked Expression of Interest, etc...

# Participation in Expressions of Interest submitted to the IMI JU



PILLAR	Number of Teams (%)						TOTAL
	Academic	SMEs	Patients organisations	Regulatory agencies	Large non-EFPIA companies	Industry associations	
Safety	269 (69%)	98 (25%)	5 (1%)	18 (5%)	0	0	390
Efficacy	592 (81%)	102 (14%)	32 (4%)	2 (0,5%)	3 (0,5%)	0	731
E & T	139 (80%)	20 (12%)	7 (4%)	3 (2%)	0	4 (2%)	173
<b>TOTAL Eols</b>	<b>1000 (77%)</b>	<b>220 (17%)</b>	<b>44 (3,5%)</b>	<b>23 (2%)</b>	<b>3 (0,2%)</b>	<b>4 (0,3%)</b>	<b>1294</b>

At least one participant of each **Member States**, except Malta

Highest number of participants from 1. UK - 2. Germany - 3. Italy - 4. France - 5. The Netherlands, Spain, Sweden

At least one participant from 7 **FP7 Associated Countries**: Croatia, Iceland, Israel, Norway, Serbia, Switzerland, Turkey

At least one participant from 3 **FP7 Third Countries**: Australia, Russia, USA